resiquimod has been researched along with mannitol in 1 studies
| Studies (resiquimod) | Trials (resiquimod) | Recent Studies (post-2010) (resiquimod) | Studies (mannitol) | Trials (mannitol) | Recent Studies (post-2010) (mannitol) |
|---|---|---|---|---|---|
| 465 | 14 | 318 | 13,114 | 685 | 2,583 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, S; Bhardwaj, N; Chiriboga, L; Cruz, CM; Darvishian, F; Escalon, J; Escano, C; Gnjatic, S; Goldberg, J; Hasan, F; Holman, RM; Jungbluth, A; Mandeli, J; Muren, C; Ott, PA; Pan, L; Pavlick, A; Rolnitzsky, L; Sabado, RL; Sharpe, D; Spadaccia, M; Vasilakos, JP; Vengco, I; Venhaus, R; Yepes, E | 1 |
1 trial(s) available for resiquimod and mannitol
| Article | Year |
|---|---|
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Imidazoles; Immunity, Cellular; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Peptide Fragments; Vaccination | 2015 |